Research programme: G protein-coupled receptor modulators - Ogeda

Drug Profile

Research programme: G protein-coupled receptor modulators - Ogeda

Alternative Names: ESN-401; ESN-502; ESN-601; ESN-603; ESN-700

Latest Information Update: 18 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Euroscreen
  • Developer Euroscreen; Ogeda
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; G-protein coupled receptor 43 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Brain injuries; Parkinson's disease
  • Research Multiple sclerosis; Obesity; Rheumatoid arthritis; Type 2 diabetes mellitus; Ulcerative colitis
  • No development reported Inflammation

Most Recent Events

  • 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
  • 19 Oct 2016 Euroscreen is now called Ogeda
  • 12 Sep 2016 CSN 502 is still in preclinical development for Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis in Belgium (Euroscreen pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top